WARSAW, Ind., July 21, 2026 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its second quarter 2026 financial results on Tuesday, August 4, 2026 after the market closes. OrthoPediatrics will host a conference call on Tuesday, August 4, 2026 at 4:30 p.m. ET to discuss the results.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast will be available for replay for at least 90 days after the event.
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 90 systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 75 countries outside the United States. For more information, please visit www.orthopediatrics.com. For more information about the OrthoPediatrics Specialty Bracing portfolio, please visit www.opsb.com.
Investor Contact
Philip Trip Taylor
Gilmartin Group
philip@gilmartinir.com
415-937-5406
The article outlines how gentle chiropractic techniques support spinal alignment and movement in children and…
Collaboration creates a path to combine Signant's market-leading eCOA and digital endpoint capabilities with Lothar…
Amwell® is transforming virtual care delivery through its unified Amwell Platform, combining interoperability, clinical integration,…
US-based research peptide supplier broadens third-party analytical testing and per-batch Certificate of Analysis documentation across…
Montreal, Quebec--(Newsfile Corp. - September 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE:…
Accreditation affirms MMRO's commitment to responsible AI governance, human oversight, and clinical integrity.NOVI, Mich., Sept.…